Adds extensive life science senior experience and transactional capability to the Board of Directors Fort Collins, CO, July 1, 2020 – Cetya Therapeutics, Inc. announces the appointment of Mr. Ron A. Lowy to its Board of Directors. Mr. Lowy fills a vacant position due to the passing of Founding Scientist Robert Williams, PhD, in May. […]
This author hasn't written their bio yet.
sambasci has contributed 4 entries to our website, so far.
Drug candidate active against EGFR and KRAS mutant lung cancer cell lines Fort Collins, CO, June xx, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,676,504 and Australian Patent No. 2016229324 covering CT-102, Cetya’s proprietary HDAC inhibitor. CT-102 has demonstrated excellent activity in vitro against difficult to treat lung cell lines. […]
Novel Chemistry Allows Conjugation of Largazole Analogs to Receptor Ligands or Other Cytotoxic Agents Fort Collins, CO, January 21, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,538,534 covering Cetya’s novel ability to conjugate receptor ligands or other cytotoxic agents to its unique HDAC inhibitors, creating targeted and dual-acting anticancer compounds. […]
$1,000,000 NIH Grant will further development of Cetya’s HDAC inhibitor CT-101 for treatment of sickle cell disease Fort Collins, CO, September 17, 2019 – Cetya Therapeutics, Inc. announces the award of a $1,000,000 Phase II STTR grant from the National Heart, Lung and Blood Institute of NIH to support the in vivo assessment of its […]
- Cetya Therapeutics Appoints Ron Lowy to Board
- Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102
- Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors
- Cetya Therapeutics Announces Phase II STTR Grant Award
- Cetya Therapeutics announces advanced industries award